BROADCASTS.com

b'

Macular degeneration is the leading cause of blindness worldwide. This, especially in the aging population: you reach a certain age, and you can\\u2019t see as well as before. Up until this point, there has been no cure for macular degeneration. In the late stages of the illness, people are declared legally blind.

Enter BioTimeInc.

Francois Binette, head of product development, explains. \\u201cThe cells that are keeping the photoreceptors healthy and happy are called the \\u2018retinal pigmented epithelial\\u2019 (RPE) cells.\\u201d With aging or disease, these cells can degenerate. Without RPE cells, the eye can\\u2019t maintain its photoreceptors, and a person\\u2019s vision blurs and fades. \\u201cWe have a very robust process of making these [RPE] cells,\\u201d explains Binette.

Listen now to find out how BioTimeInc. creates and employs RPE cells to cure blindness in aging adults.

Bio:

Dr. Fran\\xe7ois Binette is Head of Global Development for Biotime Inc. Dr. Binette has over 20 years of experience driving innovation in regenerative medicine therapy development. During his first industry appointment at Genzyme Tissue Repair in Cambridge, he helped pioneer Carticel\\u2122 for cartilage repair, the first FDA BLA-approved cell therapy product for human use. He then led R&D for Biosyntech, a startup biomaterials company in Montreal applying its proprietary platform for various tissue engineering and drug delivery applications. His systematic approach to demonstrating proof of principle in various indications brought numerous corporate partnership deals helping Biosyntech through a public offering. Dr. Binette then joined the DePuy Franchise of Johnson and Johnson, the second largest orthopedic business worldwide. Dr. Binette led several innovative regenerative medicine combination product development initiatives from bench top to approved clinical trials in US and Europe. Following JNJ, Dr. Binette joined the Spinal and Biologics business unit of Medtronic, the world\\u2019s largest medical device company, developing biologics, active devices and combination products for interventional spine procedures for back pain. Dr Binette received his Ph.D. from Laval University in Qu\\xe9bec City, followed with post-doctoral training at the Sanford-Burnham institute in La Jolla, and Harvard Medical School in Boston.